Integra Lifesciences Holdings Corp (NASDAQ:IART) VP Joseph Vinhais sold 6,800 shares of the firm’s stock in a transaction on Friday, March 9th. The stock was sold at an average price of $54.13, for a total value of $368,084.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Shares of Integra Lifesciences Holdings Corp (IART) traded up $0.92 on Monday, reaching $55.77. The company’s stock had a trading volume of 384,321 shares, compared to its average volume of 510,734. Integra Lifesciences Holdings Corp has a 12 month low of $40.51 and a 12 month high of $56.42. The company has a current ratio of 2.36, a quick ratio of 1.51 and a debt-to-equity ratio of 1.85. The firm has a market cap of $4,305.41, a PE ratio of 68.01, a P/E/G ratio of 1.69 and a beta of 0.65.
Integra Lifesciences (NASDAQ:IART) last issued its quarterly earnings results on Tuesday, February 27th. The life sciences company reported $0.64 EPS for the quarter, topping the Zacks’ consensus estimate of $0.56 by $0.08. Integra Lifesciences had a return on equity of 16.94% and a net margin of 5.45%. The company had revenue of $368.60 million during the quarter, compared to analysts’ expectations of $362.64 million. During the same quarter in the previous year, the firm posted $0.52 EPS. The firm’s revenue was up 44.2% compared to the same quarter last year. equities research analysts predict that Integra Lifesciences Holdings Corp will post 2.33 EPS for the current fiscal year.
Institutional investors and hedge funds have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Integra Lifesciences by 38.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,806 shares of the life sciences company’s stock worth $182,000 after acquiring an additional 1,054 shares during the period. Zions Bancorporation acquired a new stake in Integra Lifesciences during the 3rd quarter worth about $205,000. Xact Kapitalforvaltning AB acquired a new stake in Integra Lifesciences during the 4th quarter worth about $311,000. Campbell Newman Asset Management Inc. lifted its position in Integra Lifesciences by 21.5% during the 4th quarter. Campbell Newman Asset Management Inc. now owns 6,964 shares of the life sciences company’s stock worth $333,000 after acquiring an additional 1,234 shares during the period. Finally, Stone Ridge Asset Management LLC purchased a new position in shares of Integra Lifesciences during the 4th quarter valued at about $360,000. 90.93% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This news story was published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/03/12/integra-lifesciences-holdings-corp-iart-vp-sells-368084-00-in-stock.html.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.